High call volume

Our customer contact center is currently experiencing high call volumes. We thank you for your patience.

Show More

Insulin Strategy

Recently, the U.S. Food and Drug Administration (FDA) approved the first interchangeable biosimilar insulin product indicated to improve glycemic control in adults and pediatric patients with Type I diabetes mellitus and in adults with Type 2 diabetes mellitus. Semglee-yfgn, and its authorized alternative, insulin glargine-yfgn, are biosimilars and interchangeable with Lantus, a long-acting insulin analog. Semglee-yfgn and insulin glargine-yfgn will be available on the market by the end of 2021. These new interchangeable biosimilar insulin products offer additional safe and cost-effective options for management of diabetes.

Effective January 1, 2022, Semglee-yfgn and Insulin glargine-yfgn will replace Lantus on Blue Cross Blue Shield of North Dakota (BCBSND) formularies. Lantus will be removed from formulary and will be subject to Coverage Exception and/or Prior Approval. Utilization Management policies will be updated to reflect the formulary changes and will be available for review on January 1, 2022.